Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Update

Beyond Air, Inc. (NASDAQ:XAIR) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 1,180,000 shares, a decline of 24.4% from the November 30th total of 1,560,000 shares. Based on an average daily trading volume, of 751,200 shares, the days-to-cover ratio is currently 1.6 days.

Beyond Air Trading Down 2.0 %

Shares of NASDAQ XAIR opened at $0.44 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.76 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average price is $0.48 and its two-hundred day moving average price is $0.53. Beyond Air has a 52-week low of $0.30 and a 52-week high of $2.20. The stock has a market capitalization of $31.76 million, a P/E ratio of -0.31 and a beta of -0.23.

Beyond Air (NASDAQ:XAIR) last posted its quarterly earnings results on Monday, November 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. The business had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.19 million. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. During the same period in the prior year, the company posted ($0.51) EPS. On average, analysts anticipate that Beyond Air will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Beyond Air stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Beyond Air, Inc. (NASDAQ:XAIR) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 87,568 shares of the company’s stock, valued at approximately $47,000. Point72 Asia Singapore Pte. Ltd. owned 0.19% of Beyond Air as of its most recent SEC filing. 31.50% of the stock is currently owned by hedge funds and other institutional investors.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.